Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Peripheral kynurenines as biomarkers and targets for prevention and treatment of psychiatric conditions associated with SARS-CoV-2 infection

Gregory Oxenkrug*, Paul Summergrad

Department of Psychiatry, Tufts University School of Medicine and Tufts Medical Center, Boston, MA 02111, USA

ARTICLE INFO

Keywords: Kynurenine COVID-19 Anthranilic acid Benserazide

ABSTRACT

Present review focuses on the possible role of tryptophan (Trp) – kynurenine (Kyn) pathway in the mechanism(s) of COVID-19 associated psychiatric complications. SARS-CoV-2 infection, that causes COVID-19, triggers over-production of interferon-gamma (IFNG), a pro-inflammatory cytokine. IFNG activates indoleamine 2,3-dioxygenase-1 (IDO), enzyme that catalyzes Trp conversion into Kyn, and enzymes of down-stream Kyn pathway that catalyze Kyn conversion into 3-hydroxykynurenine, kynurenic and anthranilic acids in brain and peripheral organs. We reviewed data on SARS-CoV-2 - IFNG – induced changes of peripheral Trp – Kyn pathway, considering their translational potential for personalized psychiatric care. Elevated blood levels of Trp – Kyn pathway metabolites were correlated with the severity of symptoms and predicted the negative outcomes in COVID-19 patients. Association of Trp – Kyn pathway up-regulation with psychiatric complication in non-COVID-19 patients suggests that activation of these pathways contribute to the mechanism(s) of COVID-19 associated psychiatric conditions as well. Increased risk of psychiatric complications in carriers of T (high producer) allele of polymorphic IFNG gene and elevation of serum levels of Kyn and its metabolites in interferon-alpha treated hepatitis C virus patients provides further support for such a suggestion. Assessment of blood levels of Kyn and its metabolites, and polymorphism of Trp – Kyn pathway genes might be developed into personalized biological markers predicting gender/aging dependent individual’s risk of psychiatric complications in COVID-19 patients. Up-regulation of IFNG and IDO is necessary for anti-viral protection. Therefore, inhibition of down-stream Kyn pathway should be considered as a new target for prevention/treatment of COVID-19 and COVID-19-associated psychiatric complications.

Introduction

Accumulating evidences pointed out to emergence of severe psychiatric conditions in coronavirus disease 2019 (COVID-19) patients [1]. Proposed mechanism(s) of such complications did not include dysregulation of Trp – Kyn pathway [2] despite the data on SARS-CoV-2 infection-induced overproduction of IFNG [3], an inducer of key enzymes of Trp – Kyn pathway [4], and association of IFNG-inducible up-regulation of Trp – Kyn pathway with psychiatric conditions in non-COVID-19. While IFNG stimulates Trp – Kyn pathway in microglia, specifically affected by SARS-CoV-2 [5] and peripheral organs, current review focuses on SAR – IFNG – induced changes of peripheral (e.g., plasma, serum) changes of Trp – Kyn pathway considering their translational potential for personalized psychiatric care.

Tryptophan – Kynurenine pathway

Tryptophan conversion into kynurenine

Tryptophan (Trp) is an essential (for humans) amino acid. About 3–5% of Trp is metabolized into serotonin (along methoxyindole pathway), while about 95% of non-protein Trp is metabolized along kynurenine (Kyn) pathway resulting in biosynthesis of NAD+, an ubiquitarian coenzyme involved in basic cellular processes [6] (Fig. 1). Formation of Kyn from Trp is catalyzed either by Trp-2,3-dioxygenase 2 (TDO) or by indoleamine 2,3-dioxygenase I (IDO) and 2. IDO, in difference with liver TDO, is present in most mammalian organs, including brain, lungs, blood mononuclear phagocytes, intestine, placenta, adipocytes. [2]. TDO is activated by stress hormones (e.g., cortisol) and substrate (Trp) while IDO is transcriptionally induced by pro-inflammatory cytokines, e.g., interferon-gamma (IFNG) [2].
Kynurenine down-stream pathway

One of the consequences of IFNG – inducedIDO activation is an increased availability of Kyn as a substrate for kynurenine metabolism. IFNG induces IDO, an enzyme that catalyzes the conversion of Kyn into 3HK rather than into AA [7,8]. Under physiological conditions (not at Intensive Care Unit) [19], Kyn/Trp ratios and neopterin levels were higher in SARS-CoV-2 positive than in SARS-CoV-2 negative subjects [16,18]. Kyn/Trp ratios and neopterin levels correlated with serum IFNG levels and severity of infection, and predicted poor outcome of COVID-19 disease [17,18]. Overactivation of Trp conversion into Kyn was suggested as the top pathway affected in COVID-19 patients [12].

SARS-CoV-2 infection and Down-stream kynurenine metabolism

Blood levels of KYNA and 3HK were higher in SARS-CoV-2 positive in comparison with SARS-CoV-2 negative subjects [16,17,19], most likely because of increased Kyn levels (due to IFNG-induced IDO activation) and KMO activation by IFNG [20]. The increase of plasma KYNA levels was over 2-fold in severe cases and in patients who died [12].

Data on AA blood levels in COVID-19 patients are controversial. Comparison of COVID-19 patients with control subjects revealed decreased serum AA levels in COVID-19 patients in difference with the elevated levels of all other studied Kyn [16]. Prospective study, on contrary, found elevated plasma AA levels in patients hospitalized in standard conditions (not at Intensive Care Unit) [19]. Authors suggested that presence of another molecule with the same neutral monoisotopic mass as AA (that, indeed, was decreased in COVID-19 patients) might explain the discrepancy of their results with above cited study. Elevated AA levels correlated with interleukin-18, an IFNG inducing factor. Authors found that elevation of plasma AA (but not other studied Kyn derivatives) was the best negative prognostic marker for unfavorable course of disease (e.g., transfer to ICU, mechanical ventilation, death) in COVID-19 patients. The discovery of elevated AA plasma levels in prospective study of COVID-19 patients [19] is in line with finding of elevated plasma AA levels in prospective study of hepatitis C patients treated with interferon-alpha [21]. Notably, IFNG activates kynurenase, the enzyme that catalyzes AA formation from Kyn [22].

Major psychiatric conditions associated with dysregulations of kynurenine metabolism in non-COVID-19 patients

Review of available data revealed upregulated formation of Kyn, 3HK, KYNA, and probably, AA in COVID-19 patients. These biochemical changes are known to contribute to mechanism(s) of schizophrenia, depression and anxiety in non-COVID-19 patients.

SCHIZOPHRENIA. Up-regulated KYNA formation is considered to be causatively linked with major psychopathology in schizophrenia [23]. “KYNA hypothesis” of schizophrenia suggests causative link between major psychopathology of schizophrenia and up-regulated formation of KYNA, an antagonist to NMDA receptors (NMDAR) [9,10]. Notably, IFNG activates kynurenase, a cofactor of nitric oxide synthase (Fig. 2) [13]. Therefore, evaluation of plasma/serum levels of neopterin, a stable pteridine derivative, helps to differentiate whether stress (TDO) or inflammation (IDO) is responsible for KYNA formation in Schizophrenia. IFNG, concurrently with IDO, induces guanosine triphosphate cyclohydrolase 1, a rate-limiting enzyme of biosynthesis of tetrahydrobiopterin, an immediate precursor of neurotoxic quinolinic acid (QUIN), an agonist to NMDA receptors (NMDAR). IFNG activated kynurenase, the enzyme that catalyzes AA formation from Kyn.” [22].

AA levels were elevated in plasma and serum of schizophrenia patients [11,31].

Anxiety. Plasma Kyn level and Kyn:Trp ratios were elevated and correlated with severity of anxiety in patients suffered from anxiety, in caffeine-induced anxiety in healthy volunteers and in pregnant women at the end of term, and early puerperium, in comparison with respective controls [32]. Further studies corroborated association of anxiety with dysregulation of Trp – Kyn pathway [33].

Psychiatric conditions associated with Trp – Kyn pathway dysregulations in interferon-treated patients

Depression is the most frequent (up to 50%) psychiatric complication of interferon-alpha treatment of hepatitis C virus (HCV) [34] and melanoma patients [35], although anxiety and psychoses have observed as
well. Positive correlation of Kyn/Trp ratio and neopterin levels with the severity of depression symptoms [36], and decreased content of plasma and blood platelets serotonin [37] suggests that IDO-induced shift of Trp from methoxyindole to Kyn pathways contributes to development of depression in interferon treated [38–40].

The recent prospective study found elevation of plasma AA as predictor of increased risk of major depressive disorder in interferon-treated hepatitis C virus patients [21]. AA plasma levels were associated with severity of depression symptoms in female patients with no clinical and biochemical signs of inflammation [41].

In addition to IDO-induced depletion of brain serotonin, IDO-induced imbalance between neurotoxic and neuroprotective metabolites was suggested to contribute to development of depression, probably via its effects on glutamatergic neurotransmission [9]. Notably, AA may modulate activity of NMDAR by affecting the balance between antagonists, e.g., KYNA, and agonists, e.g., D-serine (D-amino acid), considering that a single dose of one of DAAO inhibitors, benzoate, robustly elevates plasma AA levels in healthy volunteers [42], and that AA (aka, 2-aminobenzoic acid) may be deaminated in vivo into benzoate [43].

**Trp – Kyn pathway as a target for prevention/treatment of psychiatric conditions associated with SARS-CoV-2 infection**

Present review suggests that in addition to factors that were considered as contributing to development of COVID-associated psychiatric conditions [2], over-activation of Trp – Kyn pathway (via IFNG – IDO induction) contributes to development of depression, anxiety and psychoses in COVID-19 patients. Therefore, activity of IDO that catalyzes formation of Kyn from Trp; and KMO, KAT and kynase that catalyze Kyn conversion into 3HK, KYNA and AA (respectively) are the most plausible targets for prevention/treatment of psychiatric conditions associated with SARS-CoV-2 infection. However, inhibition of IFNG and IDO are not suitable targets because such intervention might severely impair immunological defense mechanisms against viral infection [44–46]. Inhibition of KAT and Kynase might be a preferable intervention. Notably, benserazide and carbidopa that already used in treatment of Parkinson’s disorder, inhibit Kynase and KAT in in vitro model [47]. We found that sub-chronic administration of benserazide to C57/Blj6 mice attenuated oланzapine-induced development of metabolic syndrome [48] apparently associated with up-regulated formation of AA and XA [49]. Future studies might explore the effect of benserazide and other inhibitors of down-stream Kyn metabolism on psychiatric conditions associated with SARS-CoV-2 infection.

**Trp – Kyn pathway metabolites as biological markers of psychiatric conditions associated with SARS-CoV-2 infection**

Association of Trp – Kyn pathway dysregulation with psychiatric diseases and elevated levels of Kyn, KYNA and AA in COVID-19 patients suggest that assessment of these metabolites might be used to identify COVID-19 patients at risk for development of psychiatric condition. Notably, Kyn and AA penetrate brain-blood barrier, and, therefore, their blood levels is expected to correlate with their brain levels [50]. On the other hand, it is reasonable to suggest that SARS-CoV-2 infection-induced overactivation of Trp – Kyn pathway is a systemic effect, not limited just to peripheral Kyn metabolism. Therefore, evaluation of plasma/serum levels of Kyn metabolites might be explored as biological markers for prediction of the risk of psychiatric complication in COVID-19 patients. Notably, polymorphism of IFNG (+874) T/A (rs2430561) gene affects the amount of IFNG protein produced in response to viral infection, and might identify patients at risk for psychiatric side effects. We previously reported that carriers of T (high producer) allele were more frequent among depressed than non-depressed IFN-alpha-treated hepatitis C patients [51]. There was no association of not functional IFNG polymorphisms (rs3824259; rs10089084 and rs35099072) with IFN-α-induced depression in hepatitis C virus patient [52]. Considering that IFNG activates kynase, that catalyzes formation of AA, a presumed negative predictor of COVID-19 outcome [19], it might be importance to explore the effect of polymorphism of IFNG and other genes impacting production of key enzymes of Trp – Kyn pathway on risk of psychiatric sideeffects in COVID-19 patients. Development of markers usable for personalized psychiatry has to consider several already known factors affecting Trp – Kyn pathway such as gender and aging. Thus, IDO activation (increased Kyn/Trp ratio) was more prominent (and positively correlated with age) in males than females SARS-CoV2-positive patients [18].

**Declaration of Competing Interest**

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:

Paul Summergrad Consultant: Mental Health Data Services, Inc, Compass Pathways Ltd, Pear Therapeutics, Cowen Stock or Stock Options: Mental Health Data Services, Inc. Quartet Health, Inc., Pear Therapeutics, Karuna Therapeutics, ATAI, Cybin. Gregory Oxenkrug has nothing to declare.

**References**

[1] Varatharaj A, Thomas N, Elliot MA, Davies, N.W.S., et al. (2020 June 25). Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study. Lancer Psychiatry. S2215-0366(20)30287-X. doi: 10.1016/S2215-0366(20)30287-X.

[2] Postoliche TT, Benros ME. Targetable biological mechanisms implicated in emergent psychiatric conditions associated with SARS-CoV-2 infection. JAMA Psychiatry 2021;78(4):353-4.

[3] Brodin P. Immune determinants of COVID-19 disease: presentation and severity. Nat Med 2021;27(1):28-33.

[4] Bianchi M, Bertini R, Ghezzi P. Induction of indoleamine dioxygenase by interferon in mice: A study with different recombinant interferons and various cytokines. Biochem Biophys Res Commun 1998;152(1):237-42.

[5] Schwabenland M, Salis H, Tanewski I, Killmer S, Lago MS, Schlaad AE, et al. Deep spatial profiling of human COVID-19 brains reveals neuroinflammation with distinct microanatomical microglia–T-cell intersections. Immunity 2021;54(7):1594–1610.e11. https://doi.org/10.1016/j.immuni.2021.06.002.

[6] Schwarz R, Bruno JP, Muchowski PJ, Wu H-Q. Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci 2012;13(7):465–77. https://doi.org/10.1038/nrn3257.

[7] Moroni F. Tryptophan metabolism and brain function: focus on kynurenine and other indole metabolites. Eur J Pharmac 1999;375(1-3):87-100.

[8] Phillips RS. Structure and mechanism of kynureninase. Arch Biochem Biophys 2014;544:69-74. doi: 10.1016/j.ab.2013.10.020. PMID: 24200862.

[9] Savitz J. Role of kynurenine metabolism pathway activation in major depressive disorders. Curr Top Behav Neurosci. 2017;31:249-67. https://doi.org/10.1007/7854_2016_12.

[10] Baranyi A, Meintzer A, Breiteneker RJ, Amouzadeh-Ghadikolai O, et al. Quinolinic Acid Responses during Interferon-alpha-Induced Depressive Symptomatology in Patients with Chronic Hepatitis C Infection - A Novel Aspect for Depression and Inflammatory Hypothesis. PLoS One 2015;10(9):e0137022. doi:10.1371/journal.pone.0137022. eCollection 2015 PMID: 26368009.

[11] Fazio F, Lionetto L, Cattaneo L, Cavallini M, Zappulla C, et al. Xanthurenic acid activates mGlur3 metabotropic glutamate receptors and is a potential trait marker for schizophrenia. Sci Rep. 2016;5(1). https://doi.org/10.1038/srep17799.

[12] Roberts I, Muelas MW, Taylor JM, Davison AS et al. Untargeted metabolomics of COVID-19 patient serum reveals potential prognostic markers of both severity and outcome DOI10.1101/2020.12.09.20246389.

[13] Oxenkrug G. Interferon-gamma-inducible kynurenines/penicillamine inflammation cascade: implications for aging and aging-associated medical and psychiatric disorders (review). J Neural Transm (Vienna) 2011;118(1):75-85.

[14] Badawy A A-B, Gilles Guillemin. The plasma [kynurenine]/[tryptophan] ratio and indoleamine 2,3-dioxygenase: time for appraisal. Int J Tryptophan Res. 2019;12: 117986/469186987987.

[15] Robertson J, Gortner JM, Nilsson S, Andersson L-M, Fuchs D, et al. Serum neopterin levels in relation to mild and severe COVID-19. BMC Infect Dis (2020) 20:9420l.

[16] Thomas T, et al. COVID-19 infection alters kynurenine and fatty acid metabolism, correlating with IL-6 levels and renal status. JCI Insight, 2020;5(14):e140327. doi: 10.1172/jci.insight.140327.

[17] Lawler N, Gray K, Kimhofer T, Boughton B et al. 2021 Systemic perturbations in distinct microanatomical microglia-T-cell interactions. Immunity 2021;54(7):1594–1610.e11. https://doi.org/10.1016/j.immuni.2021.06.002.

[18] Robertson J, Gortner JM, Nilsson S, Andersson L-M, Fuchs D, et al. Serum neopterin levels in relation to mild and severe COVID-19. BMC Infect Dis (2020) 20:9420l.
[19] Danlois F-X, Grajeda-Iglesias C, Durand S, Sautav A, Roumier M, Cantin D, et al. Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers. Cell Death Dis. 2021;12(3). https://doi.org/10.1038/s41419-021-03540-y.

[20] O’Farrell K, E. Lim, G., J. Guillem, A. Harkin. A role for glial-associated kynurenine pathway activation in modulating neuronal outgrowth and complexity. Eur Neuropsychopharmacol 2015:5296.7 doi:10.1016/S0924-977X(15)00211-X.

[21] Pawlowski T, Pawlak D, Inglot M, Zaleswka M, et al. The role of anthranilic acid in the increase of depressive symptoms and major depressive disorder during treatment for hepatitis C with pegylated interferon-alpha2a and oral ribavirin. J Psychiatry Neurosci. 2021;46(1):E166–75. https://doi.org/10.1503/jpn.190139.

[22] Alberati-Giani D, Buchli R, Malherbe P, Broger C, Lang G, Kohler C, et al. Isolation and expression of a cDNA clone encoding human kynureninase. Eur J Biochem 1996;239(2):460–8.

[23] Schwarz R, Medoff D, Tamminger CA. Increased cortical kynurenine in schizophrenia. Biol Psychiat 2001;50:521–30.

[24] Erhardt S, Schwieri L, Nilsson L, Linderholm K, Engberg G. The kynurenic acid hypothesis of schizophrenia. Physiol Behav 2007;92(1-2):203–9.

[25] Turski WA, Wnorowski A, Turski GN, Turski CA, Turski L. AhR and IDO1 in pathogenesis of Covid-19 and the “Systemic AhR Activation Syndrome” – a translational review and therapeutic perspectives. Restor Neurosci 2021;38 (2020):343–54. https://doi.org/10.3233/RNN201042.

[26] Erhardt S, Blemnov K, Nordin C, Skogh E, Lindstrom LH, Engberg G. Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci Lett 2001;313(1-2):96–8.

[27] Erhardt S, Schwieri L, Emanuelsson C, Geyer M. Endogenous kynurenic acid disrupts prepulse inhibition. Biol Psychiatry 2004;56(4):255–60.

[28] Chess AC, Simoni MK, Alling TE, Bucci DJ. Elevations of endogenous kynurenic acid produce spatial working memory deficits. Schizophr Bull 2007;33(3):797–804.

[29] Dabrowski W, Kwiecien JM, Rola R, Klapec M, Stanisz GJ, et al. (2015) Prolonged subdural infusion of kynurenic acid is associated with dose-dependent myelin damage in the rat spinal cord. PLoS One 10:e0142598.

[30] Almeida A, Quarantini L, Sampao LA, et al. Lack of association of indoleamine 2,3-dioxygenase polymorphisms with interferon-alpha -related depression in Hepatitis C patients. J Hepatol 2010;52(1):10–5.

[31] Oxenkrug G, Perianayagam M, Mikolich D, Requintina P, Shick L, Ruthazer R, et al. Plasma anthranilic acid and leptin levels predict HAM-D scores in depressed women. Int J Tryptophan Res 2021;4:11786469211016474.doi: 10.1177/11786469211016474.

[32] Steiner J, Dobrowolny H, Guust PC, Oxenkrug G. Plasma anthranilic acid and leptin levels predict HAM-D scores in depressed women. Int J Tryptophan Res 2021;4:11786469211016474.doi: 10.1177/11786469211016474.

[33] Lenzer BS, Vafai SB, Delaney NF, Clish CB, Delk AA, Pierce KA, et al. Effects of sodium benzoate, a widely used food preservative, on glucose homeostasis and metabolic profiles in humans. Mol Genet Metab. 2015;141(1):73–9. https://doi.org/10.1016/j.ymgme.2014.11.010.

[34] Subramanian V, Vaidyanathan CS. Anthranilic hydroxylase from Aspergillus niger: new type of NADPH-linked nonheme iron monoxygenase. J Bacteriol. 1984;160(2):651–5. PMID: PMC214784.

[35] Kloppeburg M, Verweij CJL, Miltenburg AM, Verhoeven AJ, et al. The influence of tetracyclines on T cell activation. Clin Exp Immunol. 1995;102(3):635–41. doi: 10.1111/j.1365-2249.1995.tb08664.x.

[36] Cai Y, Kim DJ, Takahashi T, Broadhurst DJ et al. Kynurenic acid underlies immune response to COVID-19. Pre-print.

[37] Steiner J, Dobrowolny H, Guust PC, Oxenkrug G. Plasma anthranilic acid and leptin levels predict HAM-D scores in depressed women. Int J Tryptophan Res 2021;4:11786469211016474.doi: 10.1177/11786469211016474.

[38] Myint AM, Bondy B, Baghai TC, Eser D. Tryptophan metabolism and immunogenetics in major depression: A role for interferon-gamma gene. Brain Behav Immun 2013;31:128–33.

[39] Bender DA, Smith WRD, Humm RP. Effects of benserazide on tryptophan metabolism in the mouse. Biochim Pharmacol 1977;26(17):1619–23.

[40] Oxenkrug G, Summergrad P. Benserazide, an inhibitor of peripheral kynurenine metabolism, attenuates olanzapine-induced weight gain, insulin resistance, and dyslipidemia in C57Bl/6j mice. Mol Neurobiol. 2019;57(1):135–45. PMCID: PMC674038.

[41] Myint AM, Bondy B, Baghai TC, Eser D. Tryptophan metabolism and immunogenetics in major depression: A role for interferon-gamma gene. Brain Behav Immun 2013;31:128–33.

[42] Bender DA, Smith WRD, Humm RP. Effects of benserazide on tryptophan metabolism in the mouse. Biochim Pharmacol 1977;26(17):1619–23.

[43] Oxenkrug G, Summergrad P. Benserazide, an inhibitor of peripheral kynurenine metabolism, attenuates olanzapine-induced weight gain, insulin resistance, and dyslipidemia in C57Bl/6j mice. Mol Neurobiol. 2019;57(1):135–8. https://doi.org/10.1007/s12035-018-01763-z.

[44] Cai Y, Kim DJ, Takahashi T, Broadhurst DJ et al. Kynurenic acid underlies immune response to COVID-19. Pre-print.

[45] Myint AM, Bondy B, Baghai TC, Eser D. Tryptophan metabolism and immunogenetics in major depression: A role for interferon-gamma gene. Brain Behav Immun 2013;31:128–33.

[46] Bender DA, Smith WRD, Humm RP. Effects of benserazide on tryptophan metabolism in the mouse. Biochim Pharmacol 1977;26(17):1619–23.

[47] Oxenkrug G, Summergrad P. Benserazide, an inhibitor of peripheral kynurenine metabolism, attenuates olanzapine-induced weight gain, insulin resistance, and dyslipidemia in C57Bl/6j mice. Mol Neurobiol. 2019;57(1):135–8. https://doi.org/10.1007/s12035-018-01763-z.

[48] Bender DA, Smith WRD, Humm RP. Effects of benserazide on tryptophan metabolism in the mouse. Biochim Pharmacol 1977;26(17):1619–23.

[49] Oxenkrug G, Summergrad P. Benserazide, an inhibitor of peripheral kynurenine metabolism, attenuates olanzapine-induced weight gain, insulin resistance, and dyslipidemia in C57Bl/6j mice. Mol Neurobiol. 2019;57(1):135–8. https://doi.org/10.1007/s12035-018-01763-z.

[50] Myint AM, Bondy B, Baghai TC, Eser D. Tryptophan metabolism and immunogenetics in major depression: A role for interferon-gamma gene. Brain Behav Immun 2013;31:128–33.

[51] Bender DA, Smith WRD, Humm RP. Effects of benserazide on tryptophan metabolism in the mouse. Biochim Pharmacol 1977;26(17):1619–23.

[52] Oxenkrug G, Summergrad P. Benserazide, an inhibitor of peripheral kynurenine metabolism, attenuates olanzapine-induced weight gain, insulin resistance, and dyslipidemia in C57Bl/6j mice. Mol Neurobiol. 2019;57(1):135–8. https://doi.org/10.1007/s12035-018-01763-z.